The content is available as a PDF (275.4 KB).
Bibliografía
- 1.The Cochrane library 2001 Issue 3
- 2.Taylor I.K., O´Shaughnessy K.M., Fuller R.W., Dollery C.T. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 un allergen-induced bronchoconstriction and alrway hyperreaccivity in atopic subjects. Lancet. 1991;337:690–694. doi: 10.1016/0140-6736(91)90277-v. [DOI] [PubMed] [Google Scholar]
- 3.Rasmussen J.B., Eriksson L.O., Margolskee D.J., Tagari P., Williams V.C., Andersson K.E. Leukotriene D4 receptor blockade jnhibits the immediate late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol. 1992;90:193–201. doi: 10.1016/0091-6749(92)90071-9. [DOI] [PubMed] [Google Scholar]
- 4.Leff J.A., Busse W.W., Pearlman D., Bronsky E.A., Kemp J., Hendeles L. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998:147–152. doi: 10.1056/NEJM199807163390302. [DOI] [PubMed] [Google Scholar]
- 5.Villarán C., O´Neill S.J., Helbling A., Van Noad J.A., Lee T.H. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol. 1999;104:547–553. doi: 10.1016/s0091-6749(99)70322-2. [DOI] [PubMed] [Google Scholar]
- 6.Israel E., Dermarkarian R., Rosenberg M., Sperling R., Taylor G., Rubin P. The effects of a 5-lipoxygenase inhibitor un asthma induced by cold, dry air. N Engl J Med. 1990;323:1740–1744. doi: 10.1056/NEJM199012203232505. [DOI] [PubMed] [Google Scholar]
- 7.Nasser S.M., Bell G.S., Foster S., Spruce K., MacMillan R., William A. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax. 1994;49:749–756. doi: 10.1136/thx.49.8.749. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Dahlen B., Margolskee D.J., Zetterstrom O., Dahlen S.E. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax. 1993;48:1205–1210. doi: 10.1136/thx.48.12.1205. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Holgate S.T., Anderson K.D., Rodgers E.M. Comparison of «Accolate» (zafirlukast) with sodium cromoglycate in mild to moderate asthmatic patients [abstract] Allergy. 1995;50(Suppl 26):319–320. [Google Scholar]
- 10.Malmstrom K., Rodríguez-Gómez G., Guerra J., Villaran C., Pineiro A., Wei L. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, control trial. Ann Intern Med. 1999;130:487–495. doi: 10.7326/0003-4819-130-6-199903160-00005. [DOI] [PubMed] [Google Scholar]
- 11.Laitinen L.A., Naya I.P., Binks S., Harris A. Comparative efficacy of zafirlukast and low dose steroids in asthmatics on prn b2-agonists. Eur Respir J. 1997;10(Suppl 25):419–420. [Google Scholar]
- 12.Löfdahl C.G., Reiss T.F., Leff J.A., Israel E., Noonan M.J., Finn A.F. Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BJM. 1999;319:87–90. doi: 10.1136/bmj.319.7202.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Tamaoki J., Kondo M., Sakai N., Nakata J., Takemura H., Nagai A. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med. 1997;155:1235–1240. doi: 10.1164/ajrccm.155.4.9105060. [DOI] [PubMed] [Google Scholar]
- 14.Wilson A.M., Dempsey O.J., Sims E.J., Lip-worth B.J. Evaluation of salmeterol or montelukast as, second-line therapy for asthma not controlled with inhaled corticosteroids. Chest. 2001;119:1021–1026. doi: 10.1378/chest.119.4.1021. [DOI] [PubMed] [Google Scholar]